Drug Profile
Research programme: insulin sensitisers - Ember Therapeutics
Alternative Names: PPARγ phosphorylation inhibitors - Ember TherapeuticsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ember Therapeutics
- Class Small molecules
- Mechanism of Action Cyclin-dependent kinase 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 15 Dec 2011 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)